Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT538 with mAbs in Advanced Solid Tumors
NCT05069935Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FT538 in solid tumor, breast cancer, colorectal cancer (CRC) and 3 more (9 arms), sponsored by Fate Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 1.5 years and Incidence and Severity of Adverse Events at 5 years. Started Oct 2021; status: terminated.
02
Drugs
FT538
03
Conditions
solid tumorbreast cancercolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05069935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069935.